pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
638
stories
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
endpoints
6d
Capricor soars on potential FDA review extension, filing amendments
biospace
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
6d
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
6d
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
fiercebiotech
6d
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
7d
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
7d
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
biospace
7d
FDA approves Bristol Myers' multiple myeloma successor
endpoints
7d
New Taiho, Cullinan data heats up lung cancer drug battle
biopharma dive
7d
PTC takes a chance on Sangamo’s Fabry disease gene therapy
biopharma dive
7d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
7d
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
biospace
7d
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
stat
7d
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
fiercebiotech
8d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
8d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
8d
Medtronic veteran Bill Shields crosses over to become CEO at valve disease startup
fiercebiotech
8d
Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO says
stat
8d
Eli Lilly files first lawsuits over retatrutide 'black market'
endpoints
8d
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide
biopharma dive
8d
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
biospace
8d
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits
biospace
8d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
8d
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
8d
BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations
biospace
← prev
page 3 of 22
next →
